logo-loader
viewProNAi Therapeutics

ProNAi eases back after almost doubling in trading debut

medical_350_55a9522b73caf.jpg
ProNAi is pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform.

Shares of ProNAi Therapeutics (NASDAQ:DNAI) fell a day after the clinical-stage oncology company made its trading debut following an initial public offering.

ProNAi surrendered 2.5 percent to $30.05 at 2:37 p.m. in New York. The shares almost doubled to as high as $33.75 in its trading debut yesterday.

The cancer-drug company raised $137.7 million by selling 8.1 million shares at $17 a share.

The offering followed the July 2 IPO of venture-backed diagnostics company Natera Inc., whose market value has since reached $1 billion.

ProNAi’s top venture investors included Vivo Capital, Frazier Healthcare, OrbiMed Advisors and Adams Street Partners. The Vancouver-based company trades on the Nasdaq under the ticker symbol DNAI.

Jefferies LLC and BofA Merrill Lynch acted as joint book-running managers for the offering. BofA Merrill Lynch is also serving as ProNAi's Strategic IPO Advisor. Wedbush PacGrow and SunTrust Robinson Humphrey acted as co-managers.

ProNAi is pioneering a novel class of therapeutics based on our proprietary DNA interference (DNAi) technology platform. 

The company’s lead DNAi product candidate, PNT2258, targets BCL2, a widely overexpressed oncogene that is an important gatekeeper of the programmed cell death process known as apoptosis and has been linked to many forms of cancer. 

 

Quick facts: ProNAi Therapeutics

Price: - -

NASDAQ:DNAI
Market: NASDAQ
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

European Metals back drilling at Cinovec to build confidence ahead of debt...

European Metals Holdings (LON:EMH) Keith Coughlan updates Proactive on developments at their Cinovec lithium project in the Czech Republic. The company has begun resource drilling at the Cinovec Lithium-Tin Project, with a total of 19 resource drill holes to be completed during the campaign...

18 hours, 53 minutes ago

2 min read